Fourth Quarter Total Revenue Increased 100% Year-over-Year;
GAAP Gross Margin Expanded to 56.3%, Non-GAAP to 71.6%
 

Net income of $0.8 million

Adjusted EBITDA¹ of $1.3 million

Pediatric Portfolio net revenue up 86% sequentially

First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023

$20.4 million cash balance at December 31, 2024

Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time